In the high-stakes world of pharmaceutical development, where the average cost to bring a single new drug to market now exceeds $2.6 billion, the bottleneck is rarely a lack of data—it is a lack of clarity. Pharmaceutical giants like AstraZeneca, which manages a staggering portfolio of over 100 Phase 3 clinical trials, often find themselves sitting on massive biobanks of patient samples that remain largely untapped.
Immunai, a New York-based startup, is positioning itself as the high-end “plumber” of the biotech industry, fixing the costly infrastructure issues that prevent these companies from unlocking the secrets hidden within their own archives. By leveraging a proprietary foundation model of the human immune system, Immunai has cemented its relationship with AstraZeneca, announcing a third expansion of their collaboration. Under the new agreement, Immunai is eligible to receive up to $37.5 million through 2027, as they integrate their AMICA-OS platform deeper into the pharmaceutical titan’s clinical development pipeline.
A Strategic Evolution: From Oncology to Systemic Application
The partnership between Immunai and AstraZeneca is not a recent convenience; it is a relationship forged in the crucible of the pandemic. While the formal collaboration began in late 2022, the professional history between the two organizations spans nearly five years.
The Chronology of Collaboration
- 2021–2022: Initial exploratory phases and relationship building between Immunai and AstraZeneca leadership.
- Late 2022: Formalization of the primary collaboration, focusing initially on oncology clinical programs.
- October 2025: A pivotal expansion into Inflammatory Bowel Disease (IBD), signaling a shift from oncology-exclusive research to broader immunology.
- May 2026: The third and most significant expansion, moving the platform into cardiovascular inflammation, neuroinflammation, and metabolic disorders like obesity and diabetes.
“We started in immune oncology, expanded to other oncology areas, then into immunology and inflammation, and now we’re moving into cardiovascular inflammation, neuroinflammation, and even obesity and diabetes,” said Immunai CEO Noam Solomon. “The common thread is the immune system. We’ve seen that if you can map the immune response, you can map the disease state across almost any therapeutic area.”
The “Plumbing” Problem: Why Scale Without Depth Fails
For an organization with 95,000 employees and a massive clinical footprint, the logistical hurdle of working with a startup is significant. However, the value proposition lies in Immunai’s unique methodology. While many AI-driven biotech companies focus on applying algorithms to existing, public-domain datasets, Immunai insists on generating its own high-resolution data from the source.
Solomon famously describes his role as that of a “plumber.” In his view, the industry is clogged with high-volume, low-resolution data. “A lot of big numbers in this field don’t actually lead to better decisions or better insights because the data was collected without depth,” he explains.
To illustrate, he uses the analogy of scaling a low-resolution photograph. If an image lacks sufficient pixel density, the software can stretch it, but it will never reveal the nuance between shades of blue and green. In drug development, this "color blindness" leads to failure in trial stratification and biomarker identification. Immunai’s approach is to provide an “immune MRI”—a high-resolution look at the biological reality of a patient’s state, before and after treatment.
The Science of the "Immune MRI"
The core of Immunai’s competitive advantage is the transformation of physical patient samples into digital twins. When a partner company provides clinical samples, the process follows a rigorous path:
- Biobank Extraction: Clinical trial samples—often sitting dormant in freezers—are shipped to Immunai’s laboratory in New York.
- Single-Cell Multi-omic Profiling: The team processes the samples to gain a comprehensive look at the immune system at the single-cell level.
- Data Digitization: For every patient, Immunai generates a matrix of roughly 10,000 cells. Each cell is analyzed for 37,000 gene expressions, 75 surface proteins, and VDJ sequencing.
- Correlation Analysis: The platform links these immunological features to clinical endpoints, such as progression-free survival or drug-induced toxicity.
This high-resolution, multi-omic data allows researchers to understand why a drug works for one patient and fails for another. It allows for the discovery of mechanisms of action that traditional statistical methods might miss, effectively turning raw biological specimens into actionable, predictive intelligence.
Industry Implications and Competitive Landscape
Immunai is not working in a vacuum. Its strategy of "building the foundation" has attracted significant attention. In April 2025, the company partnered with the Parker Institute for Cancer Immunotherapy to assemble one of the largest single-cell datasets for real-world immunotherapy research, drawing from over 3,700 blood samples. In early 2026, Bristol Myers Squibb also inked a multi-year partnership, confirming the industry’s hunger for the specific kind of clinical insight Immunai provides.
Why Pharma Keeps Coming Back
The repeat business from giants like AstraZeneca suggests that the "plumbing" is working. When pharmaceutical companies face common, high-cost failures, they turn to Immunai to solve:
- Trial Stratification: Identifying which patients are most likely to respond to a specific therapy.
- Biomarker Discovery: Finding a reliable signature for toxicity before it manifests in a way that terminates a trial.
- Combination Efficacy: Determining why a monotherapy is failing and which second agent might synergize effectively.
- Dosing Optimization: Using immune markers to find the "Goldilocks" zone of efficacy versus safety.
The Future of Foundation Models in Biology
The most transformative aspect of Immunai’s model is the "compounding" effect of their data. In traditional research, a small cohort of 20 patients might yield statistically insignificant results. However, because Immunai has built a foundation model on hundreds of thousands of samples, each new cohort—no matter how small—is viewed through the lens of the massive, pre-existing database.
“If you’ve built a foundation model on large-scale data, every new cohort compounds against the others,” says Solomon. “When you get a new cohort, you can resolve the signal.”
This architecture effectively democratizes high-level insights for smaller clinical trials, allowing companies to derive more value from limited data. As the industry moves toward a future defined by precision medicine, the ability to decode the immune system will likely become the single most important determinant of success.
Conclusion
The expansion of the AstraZeneca-Immunai partnership represents a wider shift in the pharmaceutical industry: a move away from the "trial and error" approach of the past and toward a data-informed, mechanistic understanding of human biology. By functioning as a high-end, specialized infrastructure provider, Immunai is helping to clear the blockages that have historically made drug development an inefficient, high-risk endeavor.
As the company continues to apply its immune-system foundation model to areas ranging from neuroinflammation to obesity, the implications for patients are profound. If the “plumbing” is finally fixed, the path from a discovery in a lab to a life-saving medicine on a hospital shelf could become faster, cheaper, and far more accurate. For AstraZeneca, and the rest of the pharmaceutical sector, the cost of not partnering with such technology is simply becoming too high to bear.
About the Author
